tradingkey.logo


Medicus Pharma Ltd

MDCX
î˜đ
āļ”āļđāđāļœāļ™āļ āļđāļĄāļīāđ‚āļ”āļĒāļĨāļ°āđ€āļ­āļĩāļĒāļ”

2.770USD

+0.340+13.99%
āļ›āļīāļ” 09/19, 16:00ETāļĢāļēāļ„āļēāļĨāđˆāļēāļŠāđ‰āļē 15 āļ™āļēāļ—āļĩ
44.14MāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
āļ‚āļēāļ”āļ—āļļāļ™P/E TTM

Intraday
1m
30m
1h
D
W
M
D

āļ§āļąāļ™āļ™āļĩāđ‰

+13.99%

5 āļ§āļąāļ™

+14.94%

1 āđ€āļ”āļ·āļ­āļ™

+41.33%

6 āđ€āļ”āļ·āļ­āļ™

-10.93%

āļ•āđ‰āļ™āļ›āļĩāļˆāļ™āļ–āļķāļ‡āļ›āļąāļˆāļˆāļļāļšāļąāļ™

+13.99%

1 āļ›āļĩ

0.00%

āļ”āļđāđāļœāļ™āļ āļđāļĄāļīāđ‚āļ”āļĒāļĨāļ°āđ€āļ­āļĩāļĒāļ”

āļ„āļ°āđāļ™āļ™āļŦāļļāđ‰āļ™ TradingKey

āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USD āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: 2025-09-19

āļ‚āđ‰āļ­āļĄāļđāļĨāđ€āļŠāļīāļ‡āļĨāļķāļ

āļĄāļđāļĨāļ„āđˆāļēāļ›āļĢāļ°āđ€āļĄāļīāļ™āļ‚āļ­āļ‡āļšāļĢāļīāļĐāļąāļ—āļ™āļĩāđ‰āļ–āļ·āļ­āļ§āđˆāļē āļĄāļđāļĨāļ„āđˆāļēāļĒāļļāļ•āļīāļ˜āļĢāļĢāļĄāđāļĨāļ°āļāļēāļĢāļĒāļ­āļĄāļĢāļąāļšāļˆāļēāļāļŠāļ–āļēāļšāļąāļ™āļ–āļ·āļ­āļ§āđˆāļē āļŠāļđāļ‡āļĄāļēāļāļ•āļĨāļ­āļ”āļŠāđˆāļ§āļ‡ 30 āļ§āļąāļ™āļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē āļ™āļąāļāļ§āļīāđ€āļ„āļĢāļēāļ°āļŦāđŒāļŦāļĨāļēāļĒāļĢāļēāļĒāđ„āļ”āđ‰āđƒāļŦāđ‰āđ€āļĢāļ•āļ•āļīāđ‰āļ‡āļšāļĢāļīāļĐāļąāļ—āļ™āļĩāđ‰āđ€āļ›āđ‡āļ™ āļ‹āļ·āđ‰āļ­āļĢāļēāļ„āļēāļŦāļļāđ‰āļ™āļāļģāļĨāļąāļ‡āđ€āļ„āļĨāļ·āđˆāļ­āļ™āđ„āļŦāļ§āđƒāļ™āļāļĢāļ­āļšāđāļ„āļšāļĢāļ°āļŦāļ§āđˆāļēāļ‡āđāļ™āļ§āļĢāļąāļšāđāļĨāļ°āđāļ™āļ§āļ•āđ‰āļēāļ™ āļ—āļģāđƒāļŦāđ‰āđ€āļŦāļĄāļēāļ°āļŠāļģāļŦāļĢāļąāļšāļāļēāļĢāđ€āļ—āļĢāļ”āđāļšāļšāļŠāļ§āļīāļ‡āđƒāļ™āļāļĢāļ­āļšāļĢāļēāļ„āļē

āļ„āļ°āđ€āđ€āļ™āļ™āļŦāļļāđ‰āļ™î˜°î˜°

āļ‚āđ‰āļ­āļĄāļđāļĨāļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡

āļ­āļąāļ™āļ”āļąāļšāđƒāļ™āļ­āļļāļ•āļŠāļēāļŦāļāļĢāļĢāļĄ
107 / 175
āļ­āļąāļ™āļ”āļąāļšāļĢāļ§āļĄ
384 / 4720
āļ­āļļāļ•āļŠāļēāļŦāļāļĢāļĢāļĄ
āđ€āļ āļŠāļąāļŠāļ āļąāļ“āļ‘āđŒ

āđāļ™āļ§āļ•āđ‰āļēāļ™ & āđāļ™āļ§āļĢāļąāļš

āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ

āđāļœāļ™āļ āļđāļĄāļīāđ€āļĢāļ”āļēāļĢāđŒ

āļĢāļēāļ„āļēāļ›āļąāļˆāļˆāļļāļšāļąāļ™
āļ„āļĢāļąāđ‰āļ‡āļāđˆāļ­āļ™

āļĢāļēāļ„āļēāđ€āļ›āđ‰āļēāļŦāļĄāļēāļĒāļ™āļąāļāļ§āļīāđ€āļ„āļĢāļēāļ°āļŦāđŒ

āļ­āđ‰āļēāļ‡āļ­āļīāļ‡āļˆāļēāļāļ™āļąāļāļ§āļīāđ€āļ„āļĢāļēāļ°āļŦāđŒāļ—āļąāđ‰āļ‡āļŦāļĄāļ” 3 āļ„āļ™
āļ‹āļ·āđ‰āļ­
āļ„āļ°āđāļ™āļ™āļ›āļąāļˆāļˆāļļāļšāļąāļ™
19.667
āļĢāļēāļ„āļēāđ€āļ›āđ‰āļēāļŦāļĄāļēāļĒ
+709.33%
āđ‚āļ­āļāļēāļŠāđƒāļ™āļāļēāļĢāđ€āļ•āļīāļšāđ‚āļ•āļ‚āļ­āļ‡āļĢāļēāļ„āļē
āļ„āļģāļŠāļĩāđ‰āđāļˆāļ‡: āļāļēāļĢāļˆāļąāļ”āļ­āļąāļ™āļ”āļąāļšāđāļĨāļ°āļĢāļēāļ„āļēāđ€āļ›āđ‰āļēāļŦāļĄāļēāļĒāđ‚āļ”āļĒāļ™āļąāļāļ§āļīāđ€āļ„āļĢāļēāļ°āļŦāđŒāļˆāļąāļ”āļ—āļģāđ‚āļ”āļĒ LSEG āđ€āļžāļ·āđˆāļ­āļ§āļąāļ•āļ–āļļāļ›āļĢāļ°āļŠāļ‡āļ„āđŒāđƒāļ™āļāļēāļĢāđƒāļŦāđ‰āļ‚āđ‰āļ­āļĄāļđāļĨāđ€āļ—āđˆāļēāļ™āļąāđ‰āļ™ āđāļĨāļ°āđ„āļĄāđˆāļ–āļ·āļ­āđ€āļ›āđ‡āļ™āļ„āļģāđāļ™āļ°āļ™āļģāđƒāļ™āļāļēāļĢāļĨāļ‡āļ—āļļāļ™

āļˆāļļāļ”āđ€āļ”āđˆāļ™āļ‚āļ­āļ‡āļšāļĢāļīāļĐāļąāļ—

āļˆāļļāļ”āđāļ‚āđ‡āļ‡āļ„āļ§āļēāļĄāđ€āļŠāļĩāđˆāļĒāļ‡
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets. Its subsidiaries include SkinJect, Inc, and Medicus Pharma Inc. The Company’s wholly owned subsidiary, SkinJect, Inc (SkinJect), is focused on commercializing a novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumor cells. The Company’s wholly owned subsidiaries are focused on the development of a drug delivery system using a dissolvable microneedle array for the treatment of certain skin cancers. The Company investigates opportunities across all therapeutic areas where an unmet need exists for improved patient safety and efficacy. The Company is actively exploring expanding its drug development pipeline through qualified and accretive acquisitions and partnerships.
āļāļēāļĢāđ€āļ•āļīāļšāđ‚āļ•āļ‚āļ­āļ‡āļāļģāđ„āļĢāļŠāļđāļ‡
āļāļģāđ„āļĢāļŠāļļāļ—āļ˜āļīāļ‚āļ­āļ‡āļšāļĢāļīāļĐāļąāļ—āļ­āļĒāļđāđˆāđƒāļ™āļĢāļ°āļ”āļąāļšāļœāļđāđ‰āļ™āļģāļ­āļļāļ•āļŠāļēāļŦāļāļĢāļĢāļĄ āđ‚āļ”āļĒāļĄāļĩāļāļģāđ„āļĢāļŠāļļāļ—āļ˜āļīāļ›āļĢāļ°āļˆāļģāļ›āļĩāļĨāđˆāļēāļŠāļļāļ”āļĢāļ§āļĄ USD 559.16
āļĄāļđāļĨāļ„āđˆāļēāļĒāļļāļ•āļīāļ˜āļĢāļĢāļĄ
PE āļĨāđˆāļēāļŠāļļāļ”āļ‚āļ­āļ‡āļšāļĢāļīāļĐāļąāļ—āļ­āļĒāļđāđˆāļ—āļĩāđˆ -2.10 āļ‹āļķāđˆāļ‡āļ­āļĒāļđāđˆāđƒāļ™āļŠāđˆāļ§āļ‡āđ€āļ›āļ­āļĢāđŒāđ€āļ‹āđ‡āļ™āđ„āļ—āļĨāđŒāļ›āļēāļ™āļāļĨāļēāļ‡āļ‚āļ­āļ‡āļĢāļ­āļš 3 āļ›āļĩ
āļāļēāļĢāđ€āļ‚āđ‰āļēāļ‹āļ·āđ‰āļ­āđ‚āļ”āļĒāļŠāļ–āļēāļšāļąāļ™
āļāļēāļĢāļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļĨāđˆāļēāļŠāļļāļ”āđ‚āļ”āļĒāļŠāļ–āļēāļšāļąāļ™āļ­āļĒāļđāđˆāļ—āļĩāđˆ 10.21M āļŦāļļāđ‰āļ™ āđ€āļžāļīāđˆāļĄāļ‚āļķāđ‰āļ™ 1.05% āđāļšāļšāđ„āļ•āļĢāļĄāļēāļŠāļ•āđˆāļ­āđ„āļ•āļĢāļĄāļēāļŠ

āļ‚āđˆāļēāļ§āļŠāļēāļĢ

āļˆāļ°āļĄāļĩāļ‚āđˆāļēāļ§āļŠāļēāļĢāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāđ€āļĢāđ‡āļ§āđ† āļ™āļĩāđ‰ āđ‚āļ›āļĢāļ”āļ•āļīāļ”āļ•āļēāļĄ...

āļ•āļąāļ§āļŠāļĩāđ‰āļ§āļąāļ”āļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™î˜

EPS

āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ

āļĢāļēāļĒāđ„āļ”āđ‰āļĢāļ§āļĄ

āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ

āļšāļĢāļīāļĐāļąāļ—

Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets. Its subsidiaries include SkinJect, Inc, and Medicus Pharma Inc. The Company’s wholly owned subsidiary, SkinJect, Inc (SkinJect), is focused on commercializing a novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumor cells. The Company’s wholly owned subsidiaries are focused on the development of a drug delivery system using a dissolvable microneedle array for the treatment of certain skin cancers. The Company investigates opportunities across all therapeutic areas where an unmet need exists for improved patient safety and efficacy. The Company is actively exploring expanding its drug development pipeline through qualified and accretive acquisitions and partnerships.
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™MDCX
āļšāļĢāļīāļĐāļąāļ—Medicus Pharma Ltd
āļ‹āļĩāļ­āļĩāđ‚āļ­Dr. Raza Bokhari, M.D.
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒhttps://medicuspharma.com/
KeyAI
î™